Evidence map›Paper›PMID 30668249›Full record

ArticlemAbs2019

Dilute-and-shoot analysis of therapeutic monoclonal antibody variants in fermentation broth: a method capability study.

Christof Regl, Therese Wohlschlager, Wolfgang Esser-Skala, Iris Wagner, Martin Samonig, Johann Holzmann, Christian G Huber

Open access · goldAbstract read
In one paragraph

Article in mAbs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Christof Regla Department of Biosciences, Bioanalytical Research Labs , University of Salzburg , Salzburg , Austria.ORCID 0000-0002-7938-4494
Therese Wohlschlagera Department of Biosciences, Bioanalytical Research Labs , University of Salzburg , Salzburg , Austria.ORCID 0000-0001-9359-6744
Wolfgang Esser-Skalaa Department of Biosciences, Bioanalytical Research Labs , University of Salzburg , Salzburg , Austria.ORCID 0000-0002-7350-4045
Iris Wagnera Department of Biosciences, Bioanalytical Research Labs , University of Salzburg , Salzburg , Austria.ORCID 0000-0001-9198-4532
Martin Samoniga Department of Biosciences, Bioanalytical Research Labs , University of Salzburg , Salzburg , Austria.
Johann Holzmannb Christian Doppler Laboratory for Innovative Tools for Biosimilar Characterization , University of Salzburg , Salzburg , Austria.ORCID 0000-0003-2622-4072
Christian G Hubera Department of Biosciences, Bioanalytical Research Labs , University of Salzburg , Salzburg , Austria.ORCID 0000-0001-8358-1880
University of Salzburg · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) are widely applied as highly specific and efficient therapeutic agents for various medical conditions, including cancer, inflammatory and autoimmune diseases. As protein production in cellular systems inherently generates a multitude of molecular variants, manufacturing of mAbs requires stringent control in order to ensure safety and efficacy of the drugs. Moreover, monitoring of mAb variants in the course of the fermentation process may allow instant tuning of process parameters to maintain optimal cell culture conditions. Here, we describe a fast and robust workflow for the characterization of mAb variants in fermentation broth. Sample preparation is minimal in that the fermentation broth is shortly centrifuged before dilution and HPLC-MS analysis in a short 15-min gradient run. In a single analysis, N-glycosylation and truncation variants of the expressed mAb are identified at the intact protein level. Simultaneously, absolute quantification of mAb content in fermentation broth is achieved. The whole workflow features excellent robustness as well as retention time and peak area stability. Additional enzymatic removal of N-glycans enables determination of mAb glycation levels, which are subsequently considered in relative N-glycoform quantification to correct for isobaric galactosylation. Several molecular attributes of the expressed therapeutic protein may thus be continuously monitored to ensure the desired product profile. Application of the described workflow in an industrial environment may therefore substantially enhance in-process control in mAb production, as well as targeted biosimilar development.

Indexed as

Antibodies, MonoclonalPolysaccharidesChromatography, High Pressure LiquidGlycosylationHumansMass SpectrometryAntibodies, MonoclonalPolysaccharidesantibody subunitsbiosimilarelectrospray ionization mass spectrometryfermentationglycationglycosylationhigh-performance liquid chromatographyMAMmonoclonal antibodiesMultiple attribute monitoringPATprocess analytical technologyprocess monitoringstructural analysis

Identifiers

PMID30668249
PMCPMC6512939
OpenAlexW2914394702

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.